S. 3209 · 119th Congress · Armed Forces and National Security

NOPAIN for Veterans Act

In committee305 words Introduced Nov 19, 2025 · Latest action Nov 19, 2025

How far it has goneStage 2 of 6
  1. IntroducedNov 19, 2025 Done
  2. CommitteeReferred to Veterans' Affairs Current stage
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

Full text

No CRS summary yet · 305 words

S. 3209 · Introduced in Senate · Nov 19, 2025

SECTION 1. SHORT TITLE.

This Act may be cited as the Non-Opioids Prevent Addiction in the Nation for Veterans Act or the NOPAIN for Veterans Act .

SEC. 2. INCLUSION OF CERTAIN NON-OPIOID PAIN MEDICATIONS IN THE NATIONAL FORMULARY OF THE DEPARTMENT OF VETERANS AFFAIRS.

(a) In general. Section 8125 of title 38, United States Code, is amended— (1) in subsection (d), by adding at the end the following new paragraph: (4) The term non-opioid pain management drug or biological product means a drug or biological product approved, granted, or cleared by the Food and Drug Administration to reduce postoperative pain, to produce postsurgical or regional analgesia, or to treat acute pain, without acting upon the body’s opioid receptors. ; (2) by redesignating subsection (d), as so amended, as subsection (e); and (3) by inserting after subsection (c) the following new subsection (d): (d) The Secretary shall include a non-opioid pain management drug or biological product in the national formulary of the Department not later than the earlier of— (1) one year after the date on which the non-opioid pain management drug or biological product becomes eligible for temporary additional payment under section 1833(t)(16)(G) of the Social Security Act ( 42 U.S.C. 1395l(t)(16)(G) ) or eligible for separate payment under section 416.174 of title 42, Code of Federal Regulations (or successor regulations); or (2) 18 months after the date on which the non-opioid pain management drug or biological product is approved by the Food and Drug Administration. .

(b) Limitation. None of the funds in the Cost of War Toxic Exposures Fund under section 324 of title 38, United States Code, may be used to carry out the amendments made by this section.

(c) Implementation. Not later than 90 days after the date of the enactment of this Act, the Secretary of Veterans Affairs shall implement the amendments made by this section.

Shown here because the text is under 500 words. Open on Congress.gov

Who lobbies on it

No lobbying filing on file names S. 3209.

Organizations that named S. 3209 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Nov 19, 2025Read twice and referred to the Committee on Veterans' Affairs.
  2. Nov 19, 2025Introduced in Senate

What members said about it

  • Statement · Press release · Dec 2, 2025 · Hyde-Smith R-MS

    HYDE-SMITH SUPPORTS BILL TO OFFER VETERANS NON-OPIOID ALTERNATIVES

    Cosponsors ‘NOPAIN for Veterans Act’ to Provide Pain Management Treatments Already Offered to Medicare Enrollees WASHINGTON, D.C. – U.S. Senator Cindy Hyde-Smith (R-Miss.) on Monday cosponsored legislation to direct the U.S. Department of…

    “It’s important that veterans have access to more pain treatment options beyond being prescribed opioids, which too often lead to misuse, addiction, and loss of life. The NOPAIN for Veterans Act would allow veterans to use proven non-opioid alternatives, which is why I support it wholeheartedly.”